Here, the authors show that lymphoma-associated C-terminal mutations in MEF2B impair its phosphorylation, leading to increased stability and transcriptional activity to promote B-cell lymphomagenesis.

Formosa Pharmaceuticals has announced the first shipment of clobetasol propionate ophthalmic suspension 0.05% (APP13007) to ...

September is Leukemia and Lymphoma Awareness Month. An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic ...

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. There are several types of DLBCL, each with their own treatment options. Diffuse large B-cell lymphoma (DLBCL ...

NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people. Looking back over the journey from our humble beginnings ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

The following is a summary of “Systemic and ocular outcomes in TB-immunoreactive patients receiving immunomodulatory therapy for non-infectious uveitis: a case-control study,” published in the July ...

Bullock, who was diagnosed with diffuse large B-cell non-Hodgkin lymphoma in the fall of 2016, said a steady supply is crucial for many people, including those with other cancers and sickle cell ...

In winning European approval, Ordspono became Regeneron’s first “bispecific” antibody drug, a class that has been in the spotlight in recent years as an alternative to costly and cumbersome CAR-T cell ...

A new Spanish study found that exercise, especially aerobic exercise, may help modulate intraocular pressure (IOP) and may serve as a complementary therapy for patients with glaucoma, according to the ...

LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of ...